The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent. These samples will first be sent to the Filothèque for temporary storage, and will then be transferred to CRCI²NA (Nantes - Angers Cancer and Immunology Research Center) for analysis with the aim of studying the mechanisms of resistance and response to BTK degraders (BTKd).
Chronic Lymphocytic Leukemia (CLL) is a malignant hematological disease of B cells, primarily observed in older adults. Although it is classified among indolent hematological malignancies, CLL exhibits significant heterogeneity, both in terms of its biological characteristics and its disease progression and the therapeutic strategies employed. In patients requiring treatment, the disease can relapse. Until recently, immunochemotherapy remained the standard treatment for this disease, but the last decade has seen the emergence of oral targeted therapies, such as Bruton's tyrosine kinase inhibitors (BKT1s) and BCL-2 inhibitors (BCL-2 inhibitors), which have profoundly altered patient prognosis. While the introduction of these two classes of drugs has led to improved prognosis, a rare but significant subgroup of patients, known as "double refractory," has emerged. These patients, exposed to both BKT and BCL-2 inhibitors and who have become refractory to both treatments, have a poor prognosis. To overcome this problem of resistance, molecules targeting the degradation of the BTK protein (BTKd) are currently under development. We propose the creation of a cohort and a biobank of samples from CLL patients who are candidates for or have been exposed to BTKd, in order to study the mechanisms of response and resistance to these molecules.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
60
This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.
CHU de Angers
Angers, France
NOT_YET_RECRUITINGCHU de Bordeaux
Bordeaux, France
NOT_YET_RECRUITINGInstitut Bergonié
Bordeaux, France
NOT_YET_RECRUITINGCHU de Clermont-Ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGCHD Vendée
La Roche-sur-Yon, France
NOT_YET_RECRUITINGCentre Léon Bernard
Lyon, France
NOT_YET_RECRUITINGInstitut Paoli-Calmettes (Marseille)
Marseille, France
NOT_YET_RECRUITINGCHU de Montpellier
Montpellier, France
NOT_YET_RECRUITINGCH Régional Universitaire de Nancy
Nancy, France
NOT_YET_RECRUITINGUniversity Hospital
Nantes, France
RECRUITING...and 4 more locations
Characterization of resistance mechanisms to CLL patients candidates or exposed to BTKd.
The primary outcome is the in-depth characterization of tumor cells and their microenvironment in CLL patients candidates or exposed to BTKd. Analyses will be performed using cellular biology (e.g., flow cytometry), molecular biology (e.g., RNA sequencing), and bioinformatics (e.g., deconvolution). Functional studies include the development of preclinical ex vivo models (2D/3D culture) and gene editing of primary cells using CRISPR/Cas9 technology, based on the expertise of Team 11 at CRCI²NA. The study will include 60 patients over a 9-year enrollment period. Each participant will be followed for 5 years, resulting in a total study duration of 14 years.
Time frame: Up to 5 years after inclusion
Development of preclinical ex vivo culture models
Establishment of 2D and 3D ex vivo culture systems using primary CLL cells to replicate tumor behavior and evaluate functional characteristics.
Time frame: Up to 5 years after inclusion
Genetic modification of primary CLL cells
Application of gene editing technologies (e.g., CRISPR/Cas9) to modify primary chronic lymphocytic leukemia cells in order to investigate gene function and resistance pathways.
Time frame: Up to 5 years after inclusion
Genomic data analysis to identify resistance-related genes
Comprehensive genomic and transcriptomic profiling of CLL samples to identify genetic alterations and expression patterns associated with resistance to BTK degraders.
Time frame: Up to 5 years after inclusion
Pharmacological targeting of novel candidate molecules
Functional validation of newly identified targets through pharmacological inhibition to assess their therapeutic potential in vitro using CLL models.
Time frame: Up to 5 years after inclusion
Generation of knockout cell lines for genes of interest
Creation of gene knockout models in CLL cell lines via CRISPR/Cas9 to explore the biological role of specific resistance-associated genes.
Time frame: Up to 5 years after inclusion
Generation of drug-resistant cell lines and comparative RNA sequencing
Development of CLL cell lines resistant to BTK degraders followed by RNA sequencing analysis to compare gene expression profiles between drug-sensitive lines and resistant cell lines.
Time frame: Up to 5 years after inclusion
Reconstruction of the tumor microenvironment using co-culture systems
Establishment of co-culture models including immune (T lymphocytes, nurse-like cells) and/or stromal cells (from lymph nodes or bone marrow) to mimic the CLL tumor microenvironment.
Time frame: Up to 5 years after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.